The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure
- PMID: 1851337
The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure
Abstract
PAF has been implicated as a mediator of shock, sepsis and MOF. The results of experimental data demonstrate that PAF induces changes characteristic of endotoxemia and sepsis, including systemic hypotension and diffuse microvascular leakage. These effects are prevented by PAF antagonists. PAF induces many of the characteristic changes of MOF, including functional impairment in the lung, kidney, gastrointestinal tract and heart. PAF antagonists will inhibit these adverse effects. PAF antagonists are now being manufactured by a number of pharmaceutical companies studying the beneficial effects of PAF antagonists in human disease. Data from these studies promise valuable information with significant clinical relevance to the practicing surgeon.
Similar articles
-
Platelet and plasma platelet-activating factor in sepsis and myocardial infarction.J Lipid Mediat Cell Signal. 1994 Mar;9(2):167-82. J Lipid Mediat Cell Signal. 1994. PMID: 8012763
-
Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: relevance to multiple systems organ failure.Crit Care Clin. 1989 Apr;5(2):331-52. Crit Care Clin. 1989. PMID: 2650821 Review.
-
Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion.J Surg Res. 1993 Nov;55(5):504-15. doi: 10.1006/jsre.1993.1176. J Surg Res. 1993. PMID: 8231170
-
1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.J Pharmacol Exp Ther. 1990 Oct;255(1):28-33. J Pharmacol Exp Ther. 1990. PMID: 2170624
-
Platelet activating factor and its role in trauma, shock, and sepsis.New Horiz. 1996 May;4(2):265-75. New Horiz. 1996. PMID: 8774801 Review.
Cited by
-
Protection against lipopolysaccharide-induced death by fluoroquinolones.Antimicrob Agents Chemother. 2000 Nov;44(11):3169-73. doi: 10.1128/AAC.44.11.3169-3173.2000. Antimicrob Agents Chemother. 2000. PMID: 11036044 Free PMC article.
-
Endothelin 1 and prostacyclin attenuate increases in hydraulic permeability caused by platelet-activating factor in rats.Shock. 2010 Jun;33(6):620-5. doi: 10.1097/SHK.0b013e3181cb8a25. Shock. 2010. PMID: 19940814 Free PMC article.
-
Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor.Biochem J. 2001 Aug 1;357(Pt 3):859-65. doi: 10.1042/0264-6021:3570859. Biochem J. 2001. PMID: 11463358 Free PMC article.
-
Clinical experience with platelet-activating factor antagonists. Past, present, and near future.Clin Rev Allergy. 1994 Winter;12(4):397-417. doi: 10.1007/BF02802302. Clin Rev Allergy. 1994. PMID: 7743464 Review. No abstract available.
-
Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis.Antimicrob Agents Chemother. 1992 Sep;36(9):1971-7. doi: 10.1128/AAC.36.9.1971. Antimicrob Agents Chemother. 1992. PMID: 1416889 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical